Every 8-K that Verona Pharma (VRNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VRNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRNA filings page.
Verona Pharma plc agreed to be acquired by Merck Sharp & Dohme LLC through a court-sanctioned English law scheme of arrangement and the transaction closed on October 7, 2025. At the effective time, each Verona ordinary share was cashed out for $13.375 and each American Depositary Share (ADS), representing eight ordinary shares, received $107. Outstanding share options, time-based restricted share units, and earned performance-based restricted share units were accelerated or converted into cash payments tied to the ADS consideration, with performance awards treated as earned at the maximum level where applicable. The filing is a formal notice of closing and the mechanics for payment and equity award treatment under the Transaction Agreement.
Verona Pharma plc reported that its shareholders have approved all proposals related to the previously announced acquisition of the company by Vol Holdings LLC, a wholly owned subsidiary of Merck Sharp & Dohme LLC, via a court-sanctioned scheme of arrangement under UK law.
At the Court Meeting, shareholders approved the scheme proposal with 558,377,989 votes in favor and 2,854,904 against, with 53 of 54 registered shareholders (98.15% of those voting) supporting it. At the General Meeting, a special resolution authorizing the board to implement the scheme and amend the articles to facilitate the transaction passed with 555,121,378 votes for, 2,757,680 against and 3,240,904 withheld.
Shareholders also approved, on an advisory and non-binding basis, potential transaction-related compensation for named executive officers, with 450,663,738 votes for, 104,385,363 against and 6,070,861 withheld. The acquisition remains subject to closing conditions, including sanction of the scheme at a Court Sanction Hearing scheduled for October 6, 2025.
Verona Pharma plc disclosed an amendment to its Employee Change in Control Severance Benefit Plan in a Form 8-K filed and signed by David Zaccardelli, Pharm. D. on September 9, 2025. The filing identifies the company’s ordinary shares (nominal value £0.05 per share) and lists the communication categories under securities rules (Rule 425, Rule 14a-12, Rule 14d-2(b), Rule 13e-4(c)). The item reported is an amendment to the severance plan; no financial tables, transaction amounts, or quantitative changes to benefits are disclosed in the provided text. The disclosure indicates a governance-level change tied to executive/employee severance arrangements but does not include details about the amendment’s terms, affected participants, or estimated costs.
Verona Pharma plc (VRNA) has signed a definitive Transaction Agreement with Merck Sharp & Dohme LLC and its subsidiary Vol Holdings LLC whereby Merck, through Bidco, will acquire 100% of Verona via an English court-sanctioned Scheme of Arrangement.
- Consideration: $13.375 in cash for each ordinary share (nominal £0.05); each American Depositary Share represents eight ordinary shares and will receive $107.00 in cash.
- Equity awards: All outstanding unvested options and time-based RSUs vest immediately before closing; in-the-money options and vested awards convert to a cash payment based on the $107 ADS price, while out-of-the-money options are cancelled.
- Conditions: Verona shareholder approval, sanction by the High Court of Justice of England & Wales, required regulatory clearances and other customary closing conditions.
- Termination provisions: Either party may walk away if the deal is not completed by 8 Jan 2026 (with up to two automatic three-month extensions for pending regulatory approvals). Verona may owe Merck a $100 million termination fee upon specified events such as Board recommendation change or acceptance of a superior proposal.
- Governance safeguards: Verona’s Board unanimously recommends the scheme; directors and certain executives have entered into a Voting Agreement to support the transaction.
- Non-solicitation: Verona is restricted from soliciting competing bids but may engage on a bona fide proposal deemed likely superior, subject to notification and other requirements.
A joint press release (Exhibit 99.1) announcing the agreement was issued on 9 Jul 2025. A proxy statement on Schedule 14A will be filed with the SEC, providing full details for shareholders.
Investor takeaway: The all-cash offer provides immediate liquidity at a fixed price and is backed by a major pharmaceutical acquirer, but completion risk remains until court, shareholder and regulatory approvals are secured.